Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P6RT
|
||||
| Former ID |
DIB019434
|
||||
| Drug Name |
compound 3
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C35H52F2N6O8S
|
||||
| InChI |
InChI=1S/C35H52F2N6O8S/c1-2-9-28(39-33(46)30(25-27-12-7-4-8-13-27)41-52(48,49)43-18-22-51-23-19-43)32(45)40-29(24-26-10-5-3-6-11-26)31(44)35(36,37)34(47)38-14-15-42-16-20-50-21-17-42/h2,4,7-8,12-13,26,28-30,41H,1,3,5-6,9-11,14-25H2,(H,38,47)(H,39,46)(H,40,45)/t28-,29-,30-/m0/s1
|
||||
| InChIKey |
MQDDTALXSBQTQP-DTXPUJKBSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | progastricsin (pepsinogen C) | Target Info | Inhibitor | [1] | |
| cathepsin E | Target Info | Inhibitor | [1] | ||
| Cathepsin D | Target Info | Inhibitor | [1] | ||
| pepsinogen 5, group I (pepsinogen A) | Target Info | Inhibitor | [1] | ||
| BioCyc Pathway | Thyroid hormone biosynthesis | ||||
| KEGG Pathway | Sphingolipid signaling pathway | ||||
| Lysosome | |||||
| Tuberculosis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | LKB1 signaling events | ||||
| Ceramide signaling pathway | |||||
| Direct p53 effectors | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Reactome | Collagen degradation | ||||
| Metabolism of Angiotensinogen to Angiotensins | |||||
| MHC class II antigen presentation | |||||
| References | |||||
| REF 1 | Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.